- Regulatory Status
- Other Names
- Monocyte chemeotactic protein 4 (MCP4), CKβ10, New CC chemokine 1 (NCC1), Small inducible cytokine subfamily a, member 13 (SCYA13)
- Ave. Rating
- Submit a Review
- Product Citations
|Cat #||Size||Price||Quantity Avail.||Save|
Human CCL13 (MCP-4) was initially identified in a library constructed from human fetal mRNA. CCL13 shares a high similarity with CCL2 (MCP-1, 61%), CCL7 (MCP-3, 58%), and CCL8 (MCP-2, 55%). CCL13 is constitutively expressed at high levels in the small intestine, colon, and lung. Original data showed that CCL13 was less effective than MCP-1 and MCP-3 in monocyte and lymphocyte chemoattraction, but equivalent to eotaxin as a chemoattractant for eosinophils. Chemokines are very important in the inflammatory process, initially in the influx of PMN by CXC chemokines and subsequently chemoattracting monocytes where the MCPs participate, including CCL13. The bioactivity of pro-inflammatory chemokines is regulated by MMPs in order to regulate the influx of different cell subpopulations. In the case of CCL13, it is inactivated by MMP-12 by truncation at position 4-5 generating a CCR antagonist and decreasing the arrival of monocytes. CCL13 binds to CCR2, and this receptor also binds to CCL2, CCL8, CCL7, CCL11, CCL24, and CCL26. CCL13 is involved in inflammatory diseases such as rheumatoid arthritis (RA), atherosclerosis, and asthma. High levels of CCL13 have been detected in the synovial fluid of patients with RA, in serum of asthmatic patients, and in plasma of patients with symptomatic carotid atherosclerosis.Product Details
- Molecular Mass
- The 75 amino acid recombinant protein has a predicted molecular mass of approximately 8.6 kD. The DTT-reduced and non-reduced protein migrate at approximately 11-13 and 14-16 kD by SDS-PAGE respectively. The N-terminal amino acid is Gln.
- >95%, as determined by Coomassie stained SDS-PAGE.
- Lyophilized in sterile-filtered PBS, pH 7.2, containing 1% BSA, 0.09% sodium azide, and protease inhibitors
- Lot-specific (please contact technical support for mass/vial, or use our Lookup tool if you have a lot number.)
- Storage & Handling
- Immediately upon receipt, store unopened vials between 2°C and 8°C and use within 12 months from date of receipt. Prior to use, reconstitute the lyophilized powder with 0.2 ml of PBS containing a carrier protein (e.g., 1% BSA, protease free), pH 7.4. Re-cap vial, vortex. Allow the reconstituted standard to sit at room temperature for 15 minutes, vortex again to mix completely. The reconstituted standard stock solution can be aliquoted into polypropylene vials and stored at -70°C for up to one month. Do not re-use diluted standards. Use a manual defrost freezer and avoid repeated freeze thaw cycles.
ELISA - Quality tested
- Recommended Usage
Each lot of this protein is quality control tested by ELISA assay. For use as an ELISA standard, a standard curve comprised of doubling dilutions from 3.9 - 250 pg/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application.
- Application Notes
This CCL13 (MCP-4) protein (Cat. No. 587509) is useful as a standard for a human CCL13 (MCP4) sandwich ELISA, using unlabeled 3G4 antibody (Cat. No. 537602) as capture and biotinylated 8C12 antibody (Cat. No. 537704) as detection.
Epithelial cells, endothelial cells, fibroblasts, chondrocytes, macrophages
- CCL13 chemoattract monocytes, eosinophils, CD4, and CD8 T cells. CCL13 induces histamine release from IL-3-primed peripheral blood basophils. IFN-γ induces CCL13 in bronchial epithelial cell lines, endothelial cells, and chondrocytes, and a synergistic effect is obtained with INF-γ and TNF-α or IL-1 in chondrocytes. CCL13 is processed and inactivated by MMP-12.
- Monocytes, dendritic cells, basophils, eosinophils, T cells
- CCR2, CCR3, and CCR5
- Cell Type
- Endothelial cells, Eosinophils, Epithelial cells, Fibroblasts, T cells
- Biology Area
- Cell Biology, Signal Transduction
- Molecular Family
- Antigen References
Uguccioni M, et al. 1996. J. Exp. Med. 183:2379.
Godiska R, et al. 1997. J. Leuko. Biol. 61:353.
Kalayci O, et al. 2004. J. Asthma 41:27.
Iwamoto T, et al. 2007. FEBS J. 274:4904.
Mendez-Enriquez E, et al. 2008. Clin. Exp. Immunol. 152:354.
Hintzen C, et al. 2009. Arthritis Rheum. 60:1932.
Dean RA, et al. 2008. Blood 112:3455.
Breland UM, et al. 2010. Cardiovasc. Res. 86:265.
- Gene ID
- 6357 View all products for this Gene ID
- View information about CCL13 on UniProt.org